HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Public ClinicalTrials.gov record NCT01856023. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Study identification
- NCT ID
- NCT01856023
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Clinigen, Inc.
- Industry
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Interventions
- High Dose Interleukin-2 Drug
- Ipilimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2013
- Primary completion
- Jun 30, 2015
- Completion
- Jun 30, 2015
- Last update posted
- Dec 4, 2023
2013 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| MSMC Research Program | Miami Beach | Florida | 33140 | — |
| Oncology Specialists, SC | Park Ridge | Illinois | 60068 | — |
| University of Iowa Hospitals & Clinics | Iowa City | Iowa | 52242 | — |
| Johns Hopkins Medicine | Lutherville | Maryland | 21093 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Nebraska Cancer Specialists, Midwest Cancer Center - Legacy | Omaha | Nebraska | 68130 | — |
| Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| Duke University Health System | Durham | North Carolina | 27710 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01856023, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01856023 live on ClinicalTrials.gov.